Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Morphotek
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Provision of Informed consent.
You may not be if
Subjects must have achieved a normalization of CA 125 levels and/or CR or PR (or stable disease and an investigator's assessment of a clinical benefit) after MORAb-003 in combination with standard chemotherapy and have not yet met the criteria for disease progression during participation in the MORAb-003-002 study.
Subjects must be currently receiving single-agent MORAb-003 maintenance therapy.
Subjects that discontinued the MORAb-003-002 study for any reason.
